NEW COMPREHENSIVE ONLINE PLATFORM:
What are falsified medicines? What is their impact? How to tackle this global challenge?
Read More
World Health Summit 2017
IFPMA session: "Antimicrobial Resistance: Moving from Talk to Action" 17th October 2017, Berlin, Germany
Read More
HealthyHorizons Campaign - The Road to Universal Health Coverage
Along with our partners, we are exploring the path to Universal Health Coverage. Join the Devex campaign “HealthyHorizons: The Road to Universal Health Coverage”.
Read More
IFPMA Corporate Brochure - Committed to a Healthier Future
We hope you find this brochure informative to gain better understanding of the contributions of our industry. We are passionate about the role we play in finding effective and sustainable solutions to today’s most pressing health concerns and look forward to continuing the dialogue with our partners
Read More
Pharma by numbers
In a simple click, find out what we bring to your country and to the world! This platform features key data and statistics for global health and pharma contribution at country and global levels.
Read More
IFPMA HEALTH PARTNERSHIPS DIRECTORY
IFPMA hosts the Health Partnerships Directory, a continuously expanding online database that allows users to view, in depth, health partnerships from across the world that involve the research-based biopharmaceutical industry.
Read More
@WIPO/GA49: Panel discussion on Patent Information Initiative for Medicines (Pat-INFORMED)
Join us here to learn more about Pat-INFORMED initiative!
Read MoreIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
The Globalisation of the Pharmaceutical Industry
Read More
The R&D-based biopharmaceutical industry at the forefront of addressing AMR
Read More
IFPMA & IFPW Supply chain session 2016 Global Health Forum - long version
The session that took place at 2016 GHF ‘Shaping a sound supply chain ecosystem’ gathered speakers from BMS, IFPW Walgreens Boots Alliance, ICRC and WHO. Moderated by Scrip’s Sukaina Virji. To find out more about the complexities of the pharmaceutical supply chain, to hear what experts think are the essential...
Read More
IFPMA contribution to key global health discussions @WHA70 (22-31 May 2017)
Geneva, 31 May 2017 – Starting with the election of Dr Tedros Adhanom Ghebreyesus as Director-General of the World Health Organization (WHO), deliberations during the 70th World Health Assembly (WHA70) in Geneva this week touched upon key public health and global security issues such as cancer prevention and control, antimicrobial...
Read More
@WHA70: Panelists take on 'Biotherapeutics & the next 70 years'
Read More
ABPI, EFPIA, and IFPMA issue joint statement on AMR
ABPI, EFPIA and IFPMA issue joint statement following publication of the final report by the Review on AMR The Association of the British Pharmaceutical Industry (ABPI), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) have today issued a joint...
Read MoreJoin IFPMA
There are many challenges in improving public health policy for current and future generations. To play an effective role in advancing these policies, the research-based biopharmaceutical industry needs an informed and credible voice in the conversation with the global health community. That voice is IFPMA.
LEARN MOREOur Blog
Adversity is the mother of invention
This blog was first published on Devex on 10 October 2017 Almost 20 years ago, in 1998, 39 leading pharmaceutical companies sued the South African government to stop legislation on parallel imports and generic substitution. It was one of the dumbest things the industry ever did. What started as a technical legal battle became a public relations disaster of unprecedented magnitude for the industry. The...
Read More
What’s the score? Universal health coverage goals discussed in New York
The headlines were about North Korea, warmongering, sanctions and, well, diplomacy. But this year’s UN General Assembly in New York in truth devoted far more time to sustainable development, climate change, mass migration and poverty – and how to provide universal health care (UHC), including for the 400 million who lack access to essential services such as immunization, family planning and even basic hospital care....
Read More
What you need to know about dementia so that you don’t forget
September is World Alzheimer’s Month, an international campaign to challenge the stigma that surrounds dementia, a disease that affects almost 150,000 people in Switzerland. It is the third most frequent cause of death in the country, costing over CHF 7 billion a year – and as many as 400,000 predominantly elderly Swiss people may live with it by 2040. More than 27,000 Swiss are newly...
Read MoreLatest Tweets
@IFPMA @IFPMA @IFPMA 
@IFPMA 